Mallotoxin is a novel human Ether-a-go-go-related gene (hERG) potassium channel activator

被引:68
作者
Zeng, Haoyu [1 ]
Lozinskaya, Irina M. [1 ]
Lin, Zuojun [1 ]
Willette, Robert N. [1 ]
Brooks, David P. [1 ]
Xu, Xiaoping [1 ]
机构
[1] GlaxoSmithKline Inc, Cardiovasc & Urogenital Ctr Excellence Drug Disco, King Of Prussia, PA 19406 USA
关键词
D O I
10.1124/jpet.106.110593
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Human ether-a-go-go-related gene (hERG) encodes a rapidly activating delayed rectifier potassium channel that plays important roles in cardiac action potential repolarization. Although many drugs and compounds block hERG channels, activators of the channel have only recently been described. Three structurally diverse synthetic compounds have been reported to activate hERG channels by altering deactivation or inactivation or by unidentified mechanisms. Here, we describe a novel, naturally occurring hERG channel activator, mallotoxin (MTX). The effects of MTX on hERG channels were investigated using the patch-clamp technique. MTX increased both step and tail hERG currents with EC50 values of 0.34 and 0.52 mu M, respectively. MTX leftward shifted the voltage dependence of hERG channel activation to less depolarized voltages (similar to 24 mV at 2.5 mu M). In addition, MTX increased hERG deactivation time constants. MTX did not change the half-maximal inactivation voltage of the hERG channel, but it reduced the slope of the voltage-dependent inactivation curve. All of these factors contribute to the enhanced activity of hERG channels. During a voltage-clamp protocol using prerecorded cardiac action potentials, 2.5 mu M MTX increased the total potassium ions passed through hERG channels by similar to 5-fold. In conclusion, MTX activates hERG channels through distinct mechanisms and with significantly higher potency than previously reported hERG channel activators.
引用
收藏
页码:957 / 962
页数:6
相关论文
共 28 条
[1]   Modulation of human erg K+ channel gating by activation of a G protein-coupled receptor and protein kinase C [J].
Barros, F ;
Gómez-Varela, D ;
Viloria, CG ;
Palomero, T ;
Giráldez, T ;
de la Peña, P .
JOURNAL OF PHYSIOLOGY-LONDON, 1998, 511 (02) :333-346
[2]   Mechanism of action of a novel human ether-a-go-go-related gene channel activator [J].
Casis, O ;
Olesen, SP ;
Sanguinetti, MC .
MOLECULAR PHARMACOLOGY, 2006, 69 (02) :658-665
[3]   Specificity and mechanism of action of some commonly used protein kinase inhibitors [J].
Davies, SP ;
Reddy, H ;
Caivano, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2000, 351 (351) :95-105
[4]   QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience [J].
De Ponti, F ;
Poluzzi, E ;
Montanaro, N .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (01) :1-18
[5]  
De Ponti F, 2002, DRUG SAFETY, V25, P263
[6]   Expression and function of KCNH2 (HERG) in the human jejunum [J].
Farrelly, AM ;
Ro, S ;
Callaghan, BP ;
Khoyi, MA ;
Fleming, N ;
Horowitz, B ;
Sanders, KM ;
Keef, KD .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2003, 284 (06) :G883-G895
[7]   ROTTLERIN, A NOVEL PROTEIN-KINASE INHIBITOR [J].
GSCHWENDT, M ;
MULLER, HJ ;
KIELBASSA, K ;
ZANG, R ;
KITTSTEIN, W ;
RINCKE, G ;
MARKS, F .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 199 (01) :93-98
[8]   ELONGATION FACTOR-II KINASE - EFFECTIVE INHIBITION BY THE NOVEL PROTEIN-KINASE INHIBITOR ROTTLERIN AND RELATIVE INSENSITIVITY TOWARDS STAUROSPORINE [J].
GSCHWENDT, M ;
KITTSTEIN, W ;
MARKS, F .
FEBS LETTERS, 1994, 338 (01) :85-88
[9]   Activation of human ether-a-go-go-related gene potassium channels by the diphenylurea 1,3-bis-(2-hydroxy-5-trifluoromethyl-phenyl)-urea (NS1643) [J].
Hansen, RS ;
Diness, TG ;
Christ, T ;
Demnitz, J ;
Ravens, U ;
Olesen, SP ;
Grunnet, M .
MOLECULAR PHARMACOLOGY, 2006, 69 (01) :266-277
[10]   Human ether-a-go-go-related gene K+ channel gating probed with extracellular Ca2+ -: Evidence for two distinct voltage sensors [J].
Johnson, JP ;
Mullins, FM ;
Bennett, PB .
JOURNAL OF GENERAL PHYSIOLOGY, 1999, 113 (04) :565-580